In vitro analysis shows taniborbactam restores susceptibility in cefiderocol-resistant Pseudomonas aeruginosa, highlighting implications for NDM resistance.
We evaluated the in vitro activity of cefiderocol in combination with either taniborbactam or xeruborbactam against cefiderocol-resistant, bla NDM -positive Pseudomonas aeruginosa clinical isolates from Vietnam and Nigeria. Taniborbactam restored cefiderocol susceptibility in most isolates (20/21, 95.2%), while xeruborbactam had no effect. Resistance was reversed by dipicolinic acid, which confirmed New-Delhi Metallo-β-Lactamase (NDM-mediated) resistance. One isolate that was unresponsive to taniborbactam carried multiple copies of bla NDM-1 . These findings highlight the species-specific limitations of xeruborbactam in P. aeruginosa .
No takes yet. Share an insight, caveat, or question.
Kocer et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: